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Definitions
Abbreviations used are MeV, measles virus; MuV, mumps virus; RbV, rubella virus;
DTT, dithiothreito1; APC, 7-amino-4-trifluoromethy1 coumarin; MOl, multiplicity of
infection; PFU, plaque forming unit; RFU, relative fluorescent unit; Adjusted RFU,
RFU values corrected by subtracting background; FBS, fetal bovine serum; EDTA,
ethylene diamine tetra acetic acid; Bulk, concentrated lot of clarified virus; Liquid
samples, non-lyophilized frozen aliquot of a specific formulation; Day 0 sample,
lyophilized non-incubated sample stored at -70°C; 1 Week 37°C sample, lyophilized
sample incubated at 37°C for 1 week.
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Abstract
In developing live virus vaccines, it is necessary to detennine viral potency and
stability to assure adequate immunization. The plaque assay is the most common method
fo{ detennining potency of live viruses. Viral stability is examined by the changes in
plaques fonned following incubation at storage temperatures or temperature to which the
vaccine may be exposed. However, the plaque assay is requires at least 7 to 10 days to
acquire viral stability. In this report, the possibility ofusing an apoptosis assay to
determine viral stability wi.th less effort and time is examined. Apoptosis, a nonnal
method of cellular suicide, can be induced via viral infection. Therefore, the
development of a quantitative assay may be used for potency and may provide
advantages compared to the plaque assay. One of the many activated proteases could be
monitored for apoptosis induction following viral infection. Specifically, the activated
protease that}s examined is caspase 3, a major protease found within the apoptosis
pathway. Using a known tetrapeptide substrate for caspase 3 linked to AFC, a
fluorescent molecule, viral stability is detennined by changes in fluorescent signal. The
stability of different fonnulations can be examined by the changes in fluorescent signal
over incubation time. The fonnulations having the best stability will correspondingly
have a greater fluorescence than that of a fonnulation with lower stability. Using this
apoptotic assay, viral stability can be examined for measles, mumps, and rubella vi~ses.
Introduction:
Apoptosis is a nonnal method of cellular suicide and plays a major role in many
biological processes (l). Various signals from the cellular environment can trigger the
cascade of events leading to apoptosis. To date, many methods that detect apoptosis
,
examine events that occur rather late in the apoptotic pathway. These methods include
leaky plasma membranes, nuclear breakdown, and chromatin condensation (2). A family
ofcysteine proteases initiates the cascade leading to nuclear breakdown and chromatin
condensation (3,4,5). One of these proteases is interleukin I-beta converting enzyme
(ICE), which is the mammalian homolog of the C. elegans ced-3 gene product (6, 7, 8,9).
The members of the ICE family are all cysteine proteases, otherwise known as caspases.
These caspases are specific for their substrates and usually have an aspartate residue at
the P4 position and require an aspartate residue at the PI position (3). Thus, protease
activity could be used as an early detection method for apoptosis..
These proteolytic enzymes, caspases, are found within cells as inactive zymogens
(9, 10). When an appropriate signal is provided, the inactive fonn is cleaved into the
active fonn. One ofthe benefits of these caspases is their great substrate specificity. By
constructing a substrate that is rec.ognized by a specific caspase, the activity of the
respective caspase can be examined independently from other caspases within a cell.
One caspase, caspase 3 (also known as CPP32 or apopain) seems to playa central role in
the apoptotic cascade and has been shown to activate other caspases including caspases 2,
6, 7, and 9 (10, 11, 12). Caspase 3 can also activate a factor involved with DNA
fragmentation (10).
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To effectively use caspase 3 as an apoptotic marker, viruses infecting cells need to
induce apoptosis. In work previously done, measles and varicella-zoster viruses can
induce apoptosis (13, 14). After induction of apoptosis via viral infection, caspase 3 will
be activated and can be used as an apoptotic marker.
The technology of this assay system stems from the use of a fluorogenic substrate.
As previously stated, caspases have high specificity for their substrates. A tetrapeptide
r
substrate, DEVD, has been identified for caspase 3 (3). By linking this DEVD peptide to
AFC, a fluorogenic compound; the activity of caspase 3 can be determined by measuring
the increase in fluorescent signal when the labeled peptide is cleaved.
In the standard plaque assay, samples are reconstituted with water and then plated
onto a cell sheet at various dilutions. The plates are then incubated for a specified length
of time then stained. Foll?wing the staining, the plaques, evidence of virus infected cells,
are counted and the corresponding plaque-forming units (PFU) determined. Viral
stability is determined by examining the decrease in PFU over time. Although effective in
determining stability, the plaque assay is very time consuming and has high variability
compared to other biochemical assays.
Using the apoptotic assay, the samples are again reconstituted, diluted, and plated
onto a cell sheet. Following incubation, the cells are lysed and the cellular material
collected. After removal of cellular debris by centrifugation, the supernatant is pooled
and stored at -70°C until assays are run. After thawing the samples, the DEVD-AFC
substrate is incubated with the cellular supernatant. Through this assay, variations•
.lyophilized samples can be determined by observations.of changes in fluorescent signal.
Along with these findings, both measles virus and mumps virus can induce apoptosis in
3
vero cells. The apoptosis assay may provide a higher throughput assay for· the
determination of viral potency and stability.
In this thesis, I show that for measles, mumps, and rubella viruses apoptosis is
induced. Along with this finding, differences between different lyophilized samples can
be observed and can be compared with the plaque data.
4
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Methods and Materials:
Growth ofVero Cells and RK-13 Cells:
Vero cells are grown to confluency in 162 cmzflasks in M199 media (Gibco/BRL
cat# 11150-059) containing 10% FBS and 0.5% neomycin at 35°C with 5% COz. The
flasks are then decanted and 3 ml of Ix trypsin-EDTA (Gibco/BRL cat# 25200-056) is
added to the flask to neutralize the media. The trypsin is decanted and another 2 mls of
trypsin is added and allowed to incubate for 10 to 15 minutes at 35°C with 5% COz. Cells
are then washed to the bottom of the flask with 20 ml ofM199 containing 10% FBS and
0;5% neomycin. Cells are plated into 24 well plates at 5.4 X 104 cells I ml. Each well
receives 2 ml of the diluted cells (Diluted into M199 containing 10% FBS and 0.5%
neomycin). T:he plates are incubated at 35°C for 2 days and then used for the apoptosis
induction. The growth ofRK-13 cells is the same as vero cells with the exception of the
media. RK-13 cells are grown in MEM media (Gibco/BRL) containing 10% FBS and
.0.5% neomycin. The cells are plated at a density of 6.0 x 104 cells Im1, 2 ml per well.
Induction of Apoptosis:
The vero plates are used for MeV and MuV infections while the RK-13 cells are
used for the RbV infections. The various lyophilized formulations ofMMR n® are
reconstituted with 0.7 ml..dHzO or the frozen liquid samples are thawed. Following
reconstitution or liquid thawing the samples are diluted 1:2, 1:5, 1:10 or 1:20 in their
respective diluents which contain the antibodies against the other two viruses found in the
MMR n® formulation. 2.0x105 cells are infected with 50ul of the diluted samples.
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Each sample is used to infect 6 wells on a 24 well plate. The plates are then incubated at
35°C with 5% CO2 for 1 hr with MuV and RbV infection and 2 hrs with MeV infection.
During this attachment phase, the plates are rocked every 15 minutes to ensure cell sheet
coverage. Following the attachment phase, the cells are overlayed with 1 mlofM199
media containing 10% FBS and 0.5% neomycin for the Vero cells and 1 mlofMEM
containing 10% FBS and 0.5% neomycin for the RK-13 cells. The plates are then
incubated at 35°C with 5% CO2 for 93 to 96 hrs.
Apoptosis Assay:
Following the induction period the media is aspirated from the wells. 30ul of
chilled cell lysis buffer (Clontech: 20mM Tris-HCI, pH7.5, 150mM NaCI,
1% Triton X -100) is added per well. The samples are incubated on ice for 10 minutes
and then two wells are pooled together into one microfuge tube. Samples can now be
frozen on dry ice and stored at -70°C until time of analysis or they can be used directly to
. '
run the assay. The samples are then spun in at 12,000 rpm for 5 minutes at 4°C. 50 ul of
the supernatant is removed to a new microfuge tube and 50 ul of2x Reaction Buffer
containing 7 mM DTT is added (Clontech: 100mM HEPES, pH 7.4, 150mM NaCl, 0.2%
CHAPS). 5 ul of the 1 mM DEVD-AFC substrate is added to the reaction and vortexed
briefly. The samples are then incubated for 1hr at 37°C in a circulating water bath.
Following the incubation, 20 ul of 10% H3P04 is used to quench the reaction. 100 ul of
the quenched reactions are added to a 96 well plate and read in a TECAN fluorescent
plate reader (excitation: 390nm emission: 480nm gain: 60). For changes in fluorescence,
the TECAN plate reader displays the data in relative fluorescent units (RFU).
6
Results
Detection of apoptosis induced by Measles, Mumps and Rubella Viruses.
Prior to using the Caspase 3 assay for viral stability, it is necessary to determine if
the three viruses under investigation can readily induce apoptosis. By inducing vero cells
with MeV and MuV and RK-13 cells with RbV, caspase 3 activity was examined using
the apoptosis detection kit supplied by Clontech. Data presented in Figure 1a, b and c
show that apoptosis could be induced in vero and RK-13 cells by measles, mumps and
rubella viruses respectively. As evident there is an eight- to ten-fold increase over the
non-induced samples.
,
Determination of the Signal actually being derived from Viral Induction or is the
Signal only a Placebo Effect.
After detecting a signal induced by viral infection, it was necessary to determine
if the signal was derived from viral infection or if the signal was a result of something
found within the formulation. To ensure that the signal that was observed was actually
due to the virus, vero cells were once again infected with a viral sample and also another
set of uninfected vero cells were infected with a placebo. The data in Figure 2 show that
the signal is in fact due to viral infection and not derived from something found within
the formulation.
.r
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Effects of Freeze-Thawing on Caspase 3 Activity.
From previous experience, it is apparent that different enzymes have different
stability profiles when they are freeze-thawed. To address this concern, following cell
lysis, samples were frozen on dry ice and stored at -70°C. These samples were then
thawed and then assayed directly with a set of samples that were not frozen. From the
results shown in Figure 3, there seems to be no effect on caspase 3 activity. By not
effecting caspase activity, many samples can be run and then stored for various lengths of
time allowing the actual assay to be run at a later time.
Determination of the Optimal Time Required for MeV Bulk Incubation ~ndMeV,
MuV and RbV Lyophilized Samples to Induce Apoptosis
The time required to induce apoptosis with various samples can be different
depending on the virus, and multiplicity of infection (MOl). To address this concern,
MeV bulk and different MeV, MuV, and RbV, lyophilized samples were used to infect
vero cells or RK-13 cells respectively. A long-term time course was set up and time
points collected at 24,46, 72, and 96 hours were taken for the bulk samples while 26,47,
75,94,95,97 and 100 hours were collected for the lyophilized samples. By examining
these time points, -the data presented in Figure 4a show that for all three viruses once
lyophilized peak around 95 hours. In Figure 4b, the optimal signal for the MeV bulk
signal was shown to be around 46 hours. This difference in overall time is expected since
a bulk sample will contain a much higher titer and be able to infect more cells much
quicker, thereby decreasing the length of time necessary to ensure an optimal signal.
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Caspase 3 Enzyme Linearity Induced with MeV and MuV
When investigating activity derived from enzymes, it is necessary to ensure that
the data collected is found within the linear range. Following apoptosis induction with
measles and mumps viruses, the samples were assayed and time points collected over a
one-hour period for the MeV assay and an hour and a half for MuV. The data in Figures
5 a and b show that the assay is linear for one hour and seems to be linear up to 75
minutes.
Determination of Non-specific Substrate Cleavage.
One of the major concerns when using a non-purified cell lysate is the effect of
non-specific substrate cleavage derived from other proteases found within the lysate.
Using a specific inhibitor for caspase 3, DEVD-CHO, the apoptosis assay was run and
analyzed. Ifnon-specific cleavage were occurring in the assay, the addition of the
inhibitor would not completely stop the substrate from being cleaved. However, the data
....
presented in Figure 6 show, with the addition of the 1uM DEVD-CHO inhibitor, the RFU
signal is not present. Samples without the caspase 3 inhibitor show a ~3000 fold increase
over the samples containing the inhibitor. Thus, non-specific cleavage is not occurring
in these cellular lysates and the signal is in fact derived from caspase 3.
The Effects of Quenching the Caspase 3 Assay using 10% H3P04
To ensure consistent data when using enzymes, it is essential to be able to quench
the reaction. This quenching will ensure that each sample is actually incubated for the
same amount of time. Following the one hour incubation period, samples were quenched
9
with 20 ul of 10% H3P04 and analyzed on the TECAN Plate reader. This data was then
compared with samples that did not undergo quenching. Looking at Figure 7, there does
seem to be a decrease in signal when compared to the non-quenched reactions. However,
on closer examination, the ratio of the non-induced samples to the induced samples is the
same. Thus, quenching the reactions does not have an effect on relative signal intensity.
Reproducibility of the Apoptosis Assay Data Derived from MeV, MuV, and RbV
Infection
One of the major problems observed with the plaque assay is the large variability
on a day-to-day basis. Along with the day-to-day variability, is the variability between
assay groups-and individuals. The scope ofthe investigation is to minimize the
variability seen day-to-day in assaying. Using samples induced by MeV, MuV, or RbV,
the reproducibility is examined by using three vials of the same sample on one day and
then it is compared to data derived using the same samples on another day of infection.
The data presented in Figures 8a, 8b, and 8c show that the assay is reproducible and very
consistent. Of the three viruses that are being investigate, MuV seems to possess the most
variability when examining the plaque data. In regards to the apoptosis data, MuV is
more consistent and the data is more reproducible.
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Effects of Dilutions on Apoptosis Signal
Using the apoptosis assay for detection ofviral stability can be a good alternative
to the plaque assay. However, prior to the assay being used, it is essential to be able to
see differences in signal when the sample is diluted to different multiplicity of infection
(MOl). To address this, a MeV and a RbV lyophilized samples were diluted 1:2, 1:5 and
1: lOin their respective diluents, while MuV was diluted 1:20, 1:40, and 1:80.. The data
presented in Figures 9a, 9b, and 9c show the effect dilutions have on all three viruses.
This is observed by the overall decrease in RFU signal as the dilution is increased. Thus
the signal can be affected by the MOl used to infect the cells.
Detection of Differences in Signal Derived from Various Lyophilized Samples.
Following the preliminary experiments, it is now time to address the question of
whether or not differences in signal can be detected with different samples and storage
conditions. To allow this assay to be an alternative to the plaque assay, differences in
signal must be observed. The data in FigureI0 show that different samples can actually
have different signals. Thus this is the first experiment that does show that the apoptosis
assay can in fact observe differences in various formulations and samples.
Comparison of the Plaque Assay to the Apoptosis Assay with MeV and MuV
Infection
For the apoptosis assay to be an alternative to the plaque assay, there must exist a
correlation between their data. Hopefully, as the PFU potency drops, one would observe
a similar drop in RFU signal. To address this concern, a stability study was examined by
11
the plaque and apoptosis assays for MeV and MuV. Data presented in Figures 11 and 12
show that as the PFU potency decreases the corresponding apoptosis signal also
~
decreases. Thus, this data strengthens the ability of the apoptosis assay to be used in
conjunction with the plaque assay as a quick screening tool in fonnulation development.
Comparison of the Plaque Assay to the Apoptosis Assay with RbV Infection.
After observing the correlation ofplaque and apoptosis data for MeV and MuV, it
was necessary to detennine ifRbV could also be compared. Of the three viruses found
within MMRII® fonnulations, RbV is the most stable. The overall stability between the
fonnulations does not vary that much which is expected. Small changes are exactly what
would be expected in the data when comparing the plaque assay to the apoptosis data.
Figure 13 shows that RbV does correlate with the plaque data. There are some minor
differences observed between the assays, however this is probably due to the overall
stability of RbV. Thus, the apoptosis assay can be used as an alternative to the plaque
assay in detennining RbV stability.
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Discussion:
The aim of this study was to develop an alternative assay to detect viral stability
for live virus vaccines and to compare the results with the standard plaque assay that is
currently used. Previously it was reported that measles, mumps, and rubella can induce
apoptosis (13, 14). One enzyme that plays a key role in the apoptotic pathway is caspase
3(10,11, 12). This investigation examined the potential of using caspase 3 activity to
determine viral stability.
To examine if caspase 3 activity was detectable upon viral infection, measles,
mumps, and rubella viruses were infected into vero and RK-13 cells respectively. A
synthetic peptide specific for caspase 3 attached to AFC, a fluorescent compound, was
used to monitor activation of caspase 3 from the crude cellular lysate. In all three viruses
caspase 3 activation was detect~d and showed a significant increase over a non-induced
sample (Figure la, b, c). Upon incubation of the crude lysate with an inhibitor for caspase
3, the activity was completely abolished. This data helped to ensure that the activity that
was being o~served was specific for caspase 3 and not related to non-specific cleavage.
After determining that all three viruses induced apoptosis and caspase 3
activation, the next step in developing the assay was to determine if differences were
observed between samples. In the plaque assay, viral stability is examined by observing
the changeQI1 the amount ofplaque forming units (PFU) over time. Liquid samples
usually have the highest PFU values followed by Day°and 1 Week 37°C samples.
However, on some occasions the day °sample had a higher titer than the liquid sample.
Thus, in the plaque assay, a stea~y decrease in PFU is observed from liquid samples
down to 1 week 37°C samples. Ifthe apoptosis assay is going to be used as an
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alternative, it was necessary to see changes in relative fluorescent unit (RFU) signal in
various samples over time. Through experiments with each virus, variations in RFU
signal could be detected between different formulations and incubation periods (Figures
11, 12, and 13). This data supports the apoptosis assay as an alternative to the plaque
assay.
In addition to seeing changes in RFU values, it was necessary to compare data
between the two assays. Using measles virus first, a direct correlation could be observed
between the PFU values and RFU values received (figure 11). Now that one of the
viruses correlated with the plaque data, both mumps and rubella data was generated. As
with measles, mumps apoptosis data seemed to correlate extremely well with the plaque
data. Only one set of data did not exactly correlate with the plaque data. This belonged
to the liquid and day 0 samples from A. However, when looking at the small increase in
PFU values between the samples, the variation could be due to either variability observed
with the plaque assay or the overall sensitivity of the apoptosis assay. Ofthe three
viruses under investigation, rubella is the most stable. Thus, the overall changes
observed between PFU values and RFU values should be minimal. The data presented in
this study does show that both assays correlate well (figure 13). Some minor differences
'are observed in formulations Hand K. However, upon comparing the log loss values for
rubella between the two assays, no differences could be observed (data not shown). For
all three viruses, it was apparent that data between the plaque assay and apoptosis assay
were comparable. Although some differences were observed, they could be attributed to
experimental error in one or both of the assays. Without further investigation this can not
yet be determined. The research presented in this study, it was apparent that the
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apoptosis assay can be used to measure viral stability and does possess some major
advantages compared to the plaque assay.
One of the major problems associated with the plaque assay is the large day-to-.
day variability and group variability. Having a large variability betweeri groups and
different days can really present problems in data interpretation. This was addressed in
regards to the correlation between the plaque and apoptosis data. By using the apoptosis
assay, it was determined that the assay is highly reproducible on a daily basis. This
reproducibility will allow a better interpretation of the data and gave us more confidence
that the assay can be used to detect viral stability. Another major advantage is time. The
standard plaque assay takes approximately seven to ten days to receive data. In the
apoptosis assay, the time is cut in half. By saving time, more formulations can be studied
and experiments undertaken. Finally, the overall simplicity and ease in running the
apoptosis assay makes it a great choice as an alternative assay.
Altho.ugh the apoptosis assay can generate viral stability data, before the assay
can be truly a replacement for the plaque assay, quantitative results must be generated.
lTo accomplish quantitative numbers, more experiments must be initiated. Through these
experiments, the variations observed between the plaque and apoptosis data can be
examined more closely. Key factors that can also be addressed include viral dilutions,
and cell plating density. These two issues could account for the variations observed.
Since caspase 3 is the enzyme under investigation for viral stability, the amount of cells
induced into apoptosis and thus the amount of caspase 3 activation can playa critical role
in the amount of signal generated. Thus, determining the correct dilution for the viruses
and the right cell density will have major impacts on comparison studies.
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In developing an alternative assay for viral stability, many factors must be
considered. Examining the data presented in this study, the apoptosis assay can be used
to generate viral stability data and hopefully will be a good alternative to the plaque assay
for a quick screening process. Overall, this study does show that differences can be
observed in various lyophilized samples and the data does correlate with the plaque data.
In the future, varicella-zoster virus and rotavirus also could be potential candidates for
this assay. However, until future investigations are completed, the apoptosis assay can be
used only to supplement data obtained from the plaque assay rather that substitute for it
altogether.
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Figure Ia: Measles V irus A poptosis
Induction
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F fgure Ic: Rubella Virus A poptosis Induction
45 0 0
4000
3 5 0 0
3 0 0 0
;J 2500
~ 2000
1 500
1 000
500
o
ICRFU
R b V Day 0 Sam p Ie
Sam pie
RbV Non-Induced
Figure I a, b, and c: Induced samples of MeV, MuV and RbV show an eight to ten
fold increase in RFU signal over their respective non-induced samples
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Figure ll: Apoptosis Placebo Effect
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Figure II: Materi'!.ls found within a lyophilized sample were not responsible for caspase
3 activation when compared to a virally infected sample.
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Figure ill: Effects of Freeze-Thawing on the
Apoptotic Signal
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Figure III: Samples freeze-thawed and then examined for caspase 3 activation showed
similar activity when compared to non-frozen samples.
19
-Figure IV a: Induction Time Course for
Apoptosis Signal
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Figure IV b: Induction Time Course with
MeV Bulk
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Figure IVa: MeV, MuV, and RbV lyophilized samples were examined for optimal
'I
signal, with the best time being 95 hours post infection. Figure IV b: A MeV bulk
sample, having a higher MOl, was shown to be optimal at approximately 46 hours post-
infection.
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Figure V a: Caspase 3 Enzyme Linearity
Assay
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Figure Vb: Caspase 3 Enzyme Linearity Assay
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Figure V a and b: Over a 75 minute time period the caspase 3 enzyme remains linear.
21
Figure VI: C aspase 3 Specificity Assay
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Figure VI: With the addition of 1uM concentration of inhibitor for caspase 3, enzyme
activity was insignificant for MeV, MuV, and RbV when compared to normally assayed
samples
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Figure Vll: Enzyme Quenching Assay
10000 .,..---:---:----
9000
8000
7000
6000
~ 5000
4000
3000
2000
1000
o
QuenchedNot Quenched Non-Induced
Not Quenched
Sample
Non-Induced
Quenched
Figure VII: Quenching of samples with lO% H3P04 shows a decrease in overall signal,
however, the ratios of non-induced to induced samples does not change.
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F ig ure V III a: MeV Rep ro due ibility
Figure VIII a, b, and c: With repeated sampling of each virus, MeV, MuV and RbV, the
RFU signal remains constant.
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F ig u re IX a: MeV D Uu tio n Exp e rim en t
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Figure IX c: RbV Dilution Experiment
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Figure IX a, b, and c: Changing the MOl affects the RFU signal for MeV, MuV and
RbV respectively. A higher MOl corresponds to a higher RFU signal.
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Figure X: MeV Induced Variation in Various
Samples
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Figure X: F?r MeV induced samples, the RFU signal showed changes with respect to the
variou;s formulations arid lengths of time the samples were incubated.
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,Figure XI: MeV Comparison Study of PFU Potency
with Apoptosis Data
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Figure XI: A correlation exists when comparing PFU potency with RFU signal for MeV
induced samples, Liq, DO, D7.
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Figure XII: MuV Comparison Study of PFU .
Potency with Apoptosis Data
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Figure XII: As PFU potency changed in MuV Liq, DO, and D7 samples, a similar effect
,
was observed for RFU signal.
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Figure Xill: RbV Comparison of Apoptosis vs.
Plaque Data
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Figure XIII: As with MeV and MuV samples, RbV Liq, DO, and D7 samples show a
similar trend"when comparing PFU potency to RFU signal.
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